Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. College of Medicine /醫學院
  3. Institute of Medicine/醫學研究所
  4. Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes
 
  • Details
Options

Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes

Journal
BMJ Open
Journal Volume
13
Journal Issue
11
Start Page
e062306
ISSN
2044-6055
2044-6055
Date Issued
2023-11
Author(s)
Peter Nash
Jan P Dutz
Steve Peterson
Barkha P Patel
Kiefer Eaton
May Shawi
Federico Zazzetti
James Cheng-Chung Wei  
DOI
10.1136/bmjopen-2022-062306
URI
https://scholars.csmu.edu.tw/handle/123456789/4857
Abstract
<jats:sec>
<jats:title>Objectives</jats:title>
<jats:p>Head-to-head clinical trials are common in psoriasis, but scarce in psoriatic arthritis (PsA), making treatment comparisons between therapeutic classes difficult. This study describes the relative effectiveness of targeted synthetic (ts) and biologic (b) disease-modifying antirheumatic drugs (DMARDs) on patient-reported outcomes (PROs) through network meta-analysis (NMA).</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Design</jats:title>
<jats:p>A systematic literature review (SLR) was conducted in January 2020. Bayesian NMAs were conducted to compare treatments on Health Assessment Questionnaire Disability Index (HAQ-DI) and 36-item Short Form (SF-36) Health Survey including Mental Component Summary (MCS) and Physical Component Summary (PCS) scores.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Data sources</jats:title>
<jats:p>Ovid MEDLINE (including Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily),Embase and Cochrane Central Register of Controlled Trials.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Eligibility criteria</jats:title>
<jats:p>Phase III randomised controlled trials (RCTs) evaluating patients with PsA receiving tsDMARDS, bDMARDs or placebo were included in the SLR; there was no restriction on outcomes.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Data extraction and synthesis</jats:title>
<jats:p>Two independent researchers reviewed all citations. Data for studies meeting all inclusion criteria were extracted into a standardised Excel-based form by one reviewer and validated by a second reviewer. A third reviewer was consulted to resolve any discrepancies, as necessary. Risk of bias was assessed using the The National Institute for Health and Care Excellence clinical effectiveness quality assessment checklist.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results</jats:title>
<jats:p>In total, 26 RCTs were included. For HAQ-DI, SF-36 PCS and SF-36 MCS scores, intravenous tumour necrosis factor (TNF) alpha inhibitors generally ranked higher than most other classes of therapies available to treat patients with PsA. For almost all outcomes, several interleukin (IL)-23, IL-17A, subcutaneous TNF and IL-12/23 agents offered comparable improvement, while cytotoxic T-lymphocyte-associated antigen 4, phosphodiesterase-4 and Janus kinase inhibitors often had the lowest efficacy.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusions</jats:title>
<jats:p>While intravenous TNFs may provide some improvements in PROs relative to several other tsDMARDs and bDMARDs for the treatment of patients with PsA, differences between classes of therapies across outcomes were small.</jats:p>
</jats:sec>
SDGs

[SDGs]SDG3

[SDGs]SDG10

Publisher
BMJ
Type
journal-article
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback